Investors

Orexo R&D Day 2026

During the day, CEO Nikolaj Sørensen and the management team will outline Orexo’s updated strategy and R&D priorities following the divestment of Zubsolv® in the US, including how the company’s proprietary drug delivery technology, AmorphOX®, underpins and drives its future development focus. The program will also feature expert perspectives from Mark A. Smith, PhD, Davidson College, NC, US, on emerging threats linked to xylazine, medetomidine, and fentanyl combinations.

Agenda and registration

Latest report

Report archive

The share

The Share

Key growth drivers and enablers for long‑term value creation

Explore

Call Q4 Interim Report - listen on demand

Press here

Listen on-demand

Stay Informed: Upcoming IR Events & Financial Calendar

Calendar – All Events

▶️View recently recorded presentations or interviews (available in English)

CEO Interview Q3 2025 Interim Report

External web link - https://www.youtube.com/watch?v=mSZADfvz2oo

BioStock: Investing in Life Science - From Seed to Success September 23 2025

External web link - https://player.vimeo.com/video/1121420399

Latest CEO Comments

Get updated here

Analysts covering Orexo

Explore

Sustainable investing

Explore

IR & Corporate Communications Director

Lena Wange

SOCIAL CORPORATE BOND

Use of proceeds, March - December 2024, and KPI deliverables

Go to report